Johnson & Johnson $JNJ Stock Holdings Decreased by Robeco Institutional Asset Management B.V.

Robeco Institutional Asset Management B.V. lowered its position in Johnson & Johnson (NYSE:JNJ) by 7.8% in the 3rd quarter, HoldingsChannel reports. The institutional investor owned 1,812,545 shares of the company’s stock after selling 153,564 shares during the quarter. Robeco Institutional Asset Management B.V.’s holdings in Johnson & Johnson were worth $479,853,000 at the end of the most recent reporting period.

A number of other institutional investors have also bought and sold shares of JNJ. Sensible Money LLC grew its stake in Johnson & Johnson by 14.8% during the third quarter. Sensible Money LLC now owns 988 shares of the company’s stock valued at $262,000 after acquiring an additional 127 shares in the last quarter. Capital Management Associates Inc lifted its stake in Johnson & Johnson by 0.5% in the 3rd quarter. Capital Management Associates Inc now owns 12,740 shares of the company’s stock worth $3,373,000 after purchasing an additional 68 shares in the last quarter. Petredis Investment Advisors LLC boosted its holdings in shares of Johnson & Johnson by 0.5% during the 3rd quarter. Petredis Investment Advisors LLC now owns 37,446 shares of the company’s stock valued at $9,913,000 after purchasing an additional 199 shares during the last quarter. Lakeshore Capital Group Inc. boosted its holdings in shares of Johnson & Johnson by 5.9% during the 3rd quarter. Lakeshore Capital Group Inc. now owns 9,944 shares of the company’s stock valued at $2,633,000 after purchasing an additional 550 shares during the last quarter. Finally, Rare Wolf Capital LLC grew its position in shares of Johnson & Johnson by 6.4% during the third quarter. Rare Wolf Capital LLC now owns 3,241 shares of the company’s stock valued at $858,000 after purchasing an additional 195 shares in the last quarter. Hedge funds and other institutional investors own 69.55% of the company’s stock.

Analyst Upgrades and Downgrades

A number of brokerages recently commented on JNJ. Wall Street Zen lowered Johnson & Johnson from a “buy” rating to a “hold” rating in a research note on Saturday, August 1st. Raymond James Financial set a $280.00 price objective on Johnson & Johnson in a research note on Monday, August 3rd. Wells Fargo & Company upped their price objective on Johnson & Johnson from $275.00 to $287.00 and gave the stock an “overweight” rating in a report on Friday, October 16th. Royal Bank Of Canada lowered their target price on Johnson & Johnson from $290.00 to $280.00 and set an “outperform” rating for the company in a research report on Wednesday, October 14th. Finally, Morgan Stanley lowered their target price on Johnson & Johnson from $294.00 to $292.00 and set an “overweight” rating for the company in a research report on Thursday, October 15th. One research analyst has rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and eight have given a Hold rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $275.92.

Insiders Place Their Bets

In other Johnson & Johnson news, EVP Elizabeth Forminard sold 15,918 shares of the company’s stock in a transaction on Thursday, August 6th. The stock was sold at an average price of $257.00, for a total transaction of $4,090,926.00. Following the completion of the sale, the executive vice president owned 16,994 shares in the company, valued at $4,367,458. This represents a 48.37% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Timothy Schmid sold 33,597 shares of the firm’s stock in a transaction dated Wednesday, September 2nd. The shares were sold at an average price of $274.74, for a total value of $9,230,439.78. Following the sale, the executive vice president directly owned 25,447 shares in the company, valued at approximately $6,991,308.78. The trade was a 56.90% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders sold 64,515 shares of company stock worth $17,271,766. 0.16% of the stock is currently owned by company insiders.

Johnson & Johnson Trading Up 3.8%

Shares of JNJ stock opened at $267.67 on Friday. The company has a market cap of $645.05 billion, a PE ratio of 40.56, a price-to-earnings-growth ratio of 2.55 and a beta of 0.21. Johnson & Johnson has a 1 year low of $184.66 and a 1 year high of $281.07. The stock’s 50 day simple moving average is $265.57 and its two-hundred day simple moving average is $250.11. The company has a debt-to-equity ratio of 0.44, a current ratio of 1.09 and a quick ratio of 0.81.

Johnson & Johnson (NYSE:JNJ) last released its earnings results on Tuesday, October 13th. The company reported $2.59 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.53 by $0.06. Johnson & Johnson had a net margin of 16.20% and a return on equity of 31.54%. The firm had revenue of $25.40 billion during the quarter, compared to analyst estimates of $25.38 billion. During the same quarter last year, the business earned $2.80 EPS. The business’s revenue was up 5.9% on a year-over-year basis. Johnson & Johnson has set its FY 2026 guidance at 11.050-11.150 EPS. Research analysts predict that Johnson & Johnson will post 11.12 earnings per share for the current year.

Johnson & Johnson Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, December 8th. Shareholders of record on Tuesday, November 24th will be given a dividend of $1.34 per share. The ex-dividend date of this dividend is Tuesday, November 24th. This represents a $5.36 dividend on an annualized basis and a yield of 2.0%. Johnson & Johnson’s payout ratio is 81.21%.

Johnson & Johnson News Roundup

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: Positive sector rotation: JNJ is benefiting from fresh demand for defensive healthcare stocks, alongside gains in Procter & Gamble and Coca-Cola. Investors appear to be favoring companies with relatively stable demand and cash flows amid broader market pressure. Procter & Gamble Jumps as Defensive Buyers Enter
• Positive Sentiment: Medical-device progress: Johnson & Johnson reported real-world data for its VARIPULSE Pro platform and 12-month outcomes for the OMNYPULSE platform in atrial-fibrillation treatment. The results could support adoption of its electrophysiology portfolio and provide another growth avenue beyond pharmaceuticals. Johnson & Johnson Reports VARIPULSE and OMNYPULSE Data
• Positive Sentiment: Drug growth and guidance: Recent coverage highlights stronger pharmaceutical performance and Johnson & Johnson’s higher 2026 outlook, with projected sales of approximately $101.2 billion at the midpoint. The company also maintains a 64-year record of annual dividend increases, reinforcing its appeal to income-focused investors. Johnson & Johnson Drugs Lift Guidance
• Neutral Sentiment: Mixed business outlook: One business is advancing strongly while another has stalled, leaving investors focused on whether new growth can justify JNJ’s premium valuation relative to competitors such as Merck and AbbVie. JNJ Stock Has a New Growth Story
• Negative Sentiment: Analyst caution and valuation risk: Erste Group Bank downgraded JNJ from “buy” to “hold.” Commentary also notes that the stock’s elevated valuation could constrain returns, particularly as Treasury yields near 5% make government bonds more competitive with dividend stocks. Erste Group Bank Ratings

Johnson & Johnson Profile

Johnson & Johnson (NYSE: JNJ) is a global healthcare company headquartered in New Brunswick, New Jersey. Founded in 1886, the company develops and markets products and services for patients, healthcare professionals and institutions worldwide.

Johnson & Johnson operates through two principal segments: Innovative Medicine and MedTech. Innovative Medicine focuses on pharmaceuticals for areas such as immunology, oncology, neuroscience, infectious diseases and cardiovascular conditions.